摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-morpholin-4-ylmethyl-benzoyl)-piperazine-1-carboxylic acid tert-butyl ester

中文名称
——
中文别名
——
英文名称
4-(4-morpholin-4-ylmethyl-benzoyl)-piperazine-1-carboxylic acid tert-butyl ester
英文别名
4-(4-Morpholin-4-ylmethyl-benzoyl)piperazine-1-carboxylic acid tert-butyl ester;tert-butyl 4-[4-(morpholin-4-ylmethyl)benzoyl]piperazine-1-carboxylate
4-(4-morpholin-4-ylmethyl-benzoyl)-piperazine-1-carboxylic acid tert-butyl ester化学式
CAS
——
化学式
C21H31N3O4
mdl
——
分子量
389.495
InChiKey
FERJZGGSAFXMCF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    28
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    62.3
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Novel Benzamide-Based Histamine H3 Receptor Antagonists: The Identification of Two Candidates for Clinical Development
    摘要:
    The preclinical characterization of novel phenyl(piperazin-1-yl)methanones that are histamine H-3 receptor antagonists is described. The compounds described are high affinity histamine H-3 antagonists. Optimization of the physical properties of these histamine H-3 antagonists led to the discovery of several promising lead compounds, and extensive preclinical profiling aided in the identification of compounds with optimal duration of action for wake promoting activity. This led to the discovery of two development candidates for Phase I and Phase II clinical trials.
    DOI:
    10.1021/ml5005156
  • 作为产物:
    描述:
    tert-butyl 4-(4-formylbenzoyl)piperazine-1-carboxylate 以48的产率得到4-(4-morpholin-4-ylmethyl-benzoyl)-piperazine-1-carboxylic acid tert-butyl ester
    参考文献:
    名称:
    ACS Med. Chem. Lett. 2015, 6, 450-454
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Mechanochemical Nucleophilic Substitution of Alcohols via Isouronium Intermediates**
    作者:Tatsiana Dalidovich、Jagadeesh Varma Nallaparaju、Tatsiana Shalima、Riina Aav、Dzmitry G. Kananovich
    DOI:10.1002/cssc.202102286
    日期:2022.2.8
    Greener amine synthesis: Nucleophilic substitution of alcohols via reactive isouronium salts under mechanochemical one-jar reaction conditions is presented for the first time. The method opens access towards biologically active amines, including active pharmaceutical ingredients.
    更环保的胺合成:首次提出了在机械化学单罐反应条件下通过反应性异脲盐对醇进行的亲核取代。该方法打开了获得生物活性胺的途径,包括活性药物成分。
  • CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR
    申请人:Allison D. Brett
    公开号:US20070066821A1
    公开(公告)日:2007-03-22
    Certain cyclopropyl amines are histamine H 3 modulators useful in the treatment of histamine H 3 receptor mediated diseases.
    某些环丙胺是组胺H3调节剂,可用于治疗组胺H3受体介导的疾病。
  • NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES
    申请人:Mani S. Neelakandha
    公开号:US20070129351A1
    公开(公告)日:2007-06-07
    The present invention is directed to novel processes for the preparation of cyclopropyl-amide derivatives, useful for the treatment of disorders and conditions mediated by the histamine receptor.
    本发明涉及一种新型的环丙基酰胺衍生物制备方法,用于治疗由组胺受体介导的疾病和病状。
  • NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES
    申请人:Mani S. Neelakandha
    公开号:US20070197508A1
    公开(公告)日:2007-08-23
    The present invention is directed to novel processes for the preparation of substituted piperazinyl and diazepanyl benzamides, useful for the treatment of disorders and conditions mediated by the histamine receptor.
    本发明涉及一种新型制备取代哌嗪基和二氮杂环巴豆酰胺的方法,可用于治疗组织胺受体介导的疾病和病况。
  • Processes for the preparation of cyclopropyl-amide derivatives
    申请人:Janssen Pharmaceutica NV
    公开号:US08063206B2
    公开(公告)日:2011-11-22
    The present invention is directed to novel processes for the preparation of cyclopropyl-amide derivatives, useful for the treatment of disorders and conditions mediated by the histamine receptor.
    本发明涉及一种新型的环丙基酰胺衍生物制备方法,用于治疗由组胺受体介导的疾病和病状。
查看更多